Soluble CD30 as a predictor of kidney graft outcome

被引:98
作者
Pelzl, S
Opelz, G
Wiesel, M
Schnülle, P
Schönemann, C
Döhler, B
Süsal, C
机构
[1] Univ Heidelberg, Dept Transplantat Immunol, Inst Immunol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Urol, Surg Clin, D-69120 Heidelberg, Germany
[3] Univ Mannheim, Dept Nephrol, Clin Internal Med, D-68167 Mannheim, Germany
[4] Charite, Bloodbank, D-13353 Berlin, Germany
关键词
D O I
10.1097/00007890-200201150-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background, In the present study, we investigated whether the soluble form of CD30 (sCD30), a marker for T helper 2-type cytokine-producing T cells, is increased in sera of potential kidney graft recipients. We also investigated whether the pretransplantation serum sCD30 content is related to kidney graft survival. Methods. Pretransplantation sera of 844 cadaver kidney recipients from three transplant centers in Germany were tested for serum sCD30 content using a commercially available ELISA kit. Results. Kidney graft recipients showed a significantly higher serum sCD30 content than healthy controls (P<0.0001). High sCD30 serum content was associated with graft rejection. The 2-year graft survival rate in recipients with a high pretransplantation serum sCD30 was 68+/-6%, significantly lower than the 86+/-1% rate in recipients with a low sCD30 (P<0.0001). Importantly, high sCD30 was indicative of an increased risk of graft loss even in recipients without lymphocytotoxic alloantibodies. Conclusion. These data show that an elevated pretransplantation serum sCD30 reflects an immune state that is detrimental for kidney graft survival.
引用
收藏
页码:3 / 6
页数:4
相关论文
共 19 条
[1]  
Del Prete G, 1998, Int Rev Immunol, V16, P427, DOI 10.3109/08830189809043004
[2]   PREFERENTIAL EXPRESSION OF CD30 BY HUMAN CD4(+) T-CELLS PRODUCING TH2-TYPE CYTOKINES [J].
DELPRETE, G ;
DECARLI, M ;
ALMERIGOGNA, F ;
DANIEL, CK ;
DELIOS, MM ;
ZANCUOGHI, G ;
VINANTE, F ;
PIZZOLO, G ;
ROMAGNANI, S .
FASEB JOURNAL, 1995, 9 (01) :81-86
[3]   MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE [J].
DURKOP, H ;
LATZA, U ;
HUMMEL, M ;
EITELBACH, F ;
SEED, B ;
STEIN, H .
CELL, 1992, 68 (03) :421-427
[4]   Soluble CD30 in pediatric patients with atopic dermatitis [J].
Frezzolini, A ;
Paradisi, M ;
Ruffelli, M ;
Cadoni, S ;
DePita, O .
ALLERGY, 1997, 52 (01) :106-109
[5]   Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy [J].
Gerli, R ;
Bistoni, O ;
Lunardi, C ;
Giacomelli, R ;
Tomassini, C ;
Biagini, P ;
Pitzalis, C .
RHEUMATOLOGY, 1999, 38 (12) :1282-1284
[6]   CD30+ T cells in rheumatoid synovitis:: Mechanisms of recruitment and functional role [J].
Gerli, R ;
Pitzalis, C ;
Bistoni, O ;
Falini, B ;
Costantini, V ;
Russano, A ;
Lunardi, C .
JOURNAL OF IMMUNOLOGY, 2000, 164 (08) :4399-4407
[7]   Molecular aspects of T- and B-cell function in uremia [J].
Girndt, M ;
Sester, M ;
Sester, U ;
Kaul, H ;
Köhler, H .
KIDNEY INTERNATIONAL, 2001, 59 :S206-S211
[8]   IL-10: A tacrolimus-specific cytotoxic mediator in ongoing allograft rejection [J].
Jiang, H ;
Yang, XF ;
Wynn, C ;
Soriano, R ;
Krishnan, K ;
Fujimura, T ;
Kobayashi, M .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :510-513
[9]   Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts [J].
Lang, T ;
Krams, SM ;
Martinez, OM .
TRANSPLANTATION, 1996, 62 (06) :776-780
[10]   Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis [J].
McMillan, SA ;
McDonnell, GV ;
Douglas, JP ;
Droogan, AG ;
Hawkins, SA .
NEUROLOGY, 1998, 51 (04) :1156-1160